Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Breaking Barriers in Antibody Drug Discovery!
2025-01-31
Our collaboration with Bio-Rad Laboratories has been featured in Manufacturing Chemist!
John Cardone, Marketing Manager at Bio-Rad Laboratories highlights the benefits of combining Salipro Biotech's Salipro® platform with the Bio-Rad PioneerTM platform. Our joint efforts are tackling critical bottlenecks in antibody drug discovery by stabilizing challenging drug targets like GPCRs, ion channels and SLC transporters with Salipro®.
The article showcases how the synergy of these two platforms creates a powerful new approach for antibody discovery, paving the way for next-generation therapeutics targeting previously inaccessible membrane proteins.
Together we are unlocking new possibilities for membrane protein targeting therapeutics.
Read the full article to see how the Salipro® and Bio-Rad PioneerTM platforms are making a difference:
https://manufacturingchemist.com/stabilised-transmembrane-proteins-to-accelerate-antibody-drug-discovery
New structural insights into drug resistance with Salipro®
2025-01-24
A recent study published in The EMBO Journal has shed light on how Salipro®-embedded ABCB1 recognizes and transports a wide range of substrates.
Role of Salipro® technology: Our Salipro® technology was pivotal in stabilizing ABCB1 in native lipid environments for native-mass spectrometry (nMS), ATPase activity assays and cryoEM.
Superior activity and stability: The Salipro®-ABCB1 particles demonstrated greater ATPase activity and a more homogenous mass distribution - compared to traditional nanodisc reconstitution methods.
High-resolution structural insights: The 3D structures of lipid-embedded human Salipro®-ABCB1 revealed the dynamic structural changes and binding site plasticity that ABCB1 undergoes when interacting with various substrates and inhibitors.
This structural and functional work unlocked with Salipro® deepens our understanding of ABCB1's mechanisms and opens new avenues for developing new drugs to bypass multidrug resistance.
Congratulations to Amer Alan and the entire research team for this contribution to understanding drug interactions and resistance mechanisms!
Read the full study here:
D. Kurre, et al., Structural insights into binding-site access and ligand recognition by human ABCB1. EMBO J. (2025).
Salipro announces a new research collaboration
2025-01-17
New Year, New Collaboration!
We’re excited to kick off the new year with a new research collaboration! With the Salipro® platform, these projects focus on the stabilization of the most challenging drug targets in the field, aiming to transform difficult membrane proteins into opportunities for therapeutic advancements.
We look forward to the advancements that these projects will bring in this year committed to our mission to make the undruggable druggable!